NSC 366140

Known as: NSC-366140 
 

Topic mentions per year

Topic mentions per year

1989-2004
01219892004

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Pyrazoloacridine (PZA) is an experimental antitumor agent presently under investigation for treatment of solid tumors on the… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2004
2004
Pyrazoloacridine (NSC 366140, PD115934, PZA) is a new class of acridine anticancer agents under investigation in Phase II… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2002
2002
Background: Pyrazoloacridine (PZA) is thefirst of a new class of rationallysynthesized acridine derivatives to undergoclinical… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
1998
1998
Pyrazoloacridine (PA), an acridine congener with an unknown mechanism of action, has shown selective activity against solid tumor… (More)
  • figure I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1997
1997
Pyrazoloacridine (PA), an acridine congener that has shown selective toxicity in solid tumor cells, full activity against… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1996
1996
Purpose. Pyrazoloacridine (PZA) is a newly developed anticancer agent currently undergoing clinical trials. Its mode of action… (More)
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
1995
1995
Pharmacokinetic studies that consisted of measuring the plasma drug profile, tissue drug distribution, and elimination in urine… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • table 3
Is this relevant?
1994
1994
BACKGROUND 9-Methoxypyrazoloacridine (PZA) is an anticancer agent that shows selectivity of action for carcinomas over leukemias… (More)
Is this relevant?
1990
1990
PD115934 (NSC 366140) is a soluble pyrazoloacridine derivative presently undergoing preclinical toxicology evaluation with the… (More)
  • figure 1
  • table 1
  • table 3
  • table 2
  • table 6
Is this relevant?
1989
1989
1. Antimetabolites and inhibitors of DNA topoisomerase II are relatively ineffective against quiescent cells. 2. Alkylating… (More)
Is this relevant?